# An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

> **NCT02068365** · PHASE4 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 41 (actual)

## Conditions studied

- Chronic Hepaititis B

## Interventions

- **DRUG:** Pegyinterferon-alfa-2a

## Key facts

- **NCT ID:** NCT02068365
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02068365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02068365, "An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02068365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*